# Herpes Zoster Reactivation After COVID-19 Vaccine with Focus on Postherpetic Neuralgia Prevention: A Case Series

## TL;DR

This case series reports four patients who developed shingles after a COVID-19 vaccine and highlights the importance of early treatment to prevent long-term pain.

## Contribution

The study emphasizes the need for early intervention to prevent chronic pain after shingles following vaccination.

## Key findings

- Four patients experienced herpes zoster reactivation after receiving a COVID-19 vaccine.
- Prompt treatment is essential to prevent postherpetic neuralgia, which can persist for years.
- Specialized analgesic support is recommended to improve quality of life in affected patients.

## Abstract

Herpes zoster (HZ), also known as shingles, is caused by the reactivation of the varicella-zoster virus (VZV). There have been several reports of HZ associated with COVID-19 vaccination, and the outcomes have varied.

In this report, we present 4 cases of patients who experienced HZ reactivation after receiving a COVID-19 vaccine. These individuals sought treatment at a pain management center due to postherpetic neuralgia (PHN). While HZ itself can be treated, post-herpetic neuralgia can persist for years, significantly impacting the patients’ quality of life. Therefore, early recognition of this adverse effect is crucial, and patients should receive specialized analgesic support promptly to prevent the development of chronic pain.